CeriBell, Inc. (NASDAQ:CBLL) is noted as one of the best medical device stocks to buy according to analysts, with J.P. Morgan setting a price target of $21.00. The company reported Q2 results, showing $21.2 million in total revenue, a 38% increase from the previous year, and a gross margin of 88%.

CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology company specializing in the diagnosis and management of patients with serious neurological conditions. Their products include Point-of-Care EEG, EEG Portal, and Clarity. The company ended Q2 2025 with 584 total active accounts.

Analysts see potential in CBLL as an investment, but suggest that certain AI stocks may offer greater upside potential with less downside risk. For those interested in an undervalued AI stock with potential benefits from Trump-era tariffs and onshoring trends, a free report on the best short-term AI stock is available.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT